Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial
Patients with metastatic melanoma treated with TIL-IMP experienced similar HRQoL compared with IPI monotherapy, with indications of better HRQoL outcomes over time. Ongoing follow-up is essential to assess longer-term HRQoL and its generalizability to a larger patient population to help guide personalized treatment decisions.
Authors
- J.B.A.G. Haanen
- Lonneke V. van de Poll‐Franse (ORCID: https://orcid.org/0000-0003-0413-6872)
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Inge Mansfield Noringriis (ORCID: https://orcid.org/0000-0001-7802-2099)
- Renske M.T. ten Ham (ORCID: https://orcid.org/0000-0002-2638-8045)
- Troels Holz Borch (ORCID: https://orcid.org/0000-0002-4402-9281)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Renée X. de Menezes (ORCID: https://orcid.org/0000-0002-1378-2721)
- C. Nijenhuis
- Melanie Lindenberg (ORCID: https://orcid.org/0000-0001-7522-1009)
- Maartje W. Rohaan (ORCID: https://orcid.org/0000-0003-1470-9427)
- Rob Kessels (ORCID: https://orcid.org/0000-0002-2479-3872)
- Wim H. van Harten (ORCID: https://orcid.org/0000-0001-9580-0489)
- Tine J. Monberg
- Inge Jedema (ORCID: https://orcid.org/0000-0001-9042-6459)
- Bastiaan Nuijen (ORCID: https://orcid.org/0000-0002-8652-3560)
- Valesca P. Retèl (ORCID: https://orcid.org/0000-0002-5624-3234)
- Maarten Egeler
- Marnix H. Geukes Foppen
Institutions
- Dutch Cancer Society (NL)
- Copenhagen University Hospital (DK)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Cancer Genomics Centre (NL)
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.annonc.2025.06.005
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09